Despite advances in medical interventions, the recurrence of stroke, particularly in patients with comorbid conditions like diabetes mellitus and obesity, is alarmingly high
Early real-world evidence for oral semaglutide supports that idea
Osteoarthritis: weight + pain In people with obesity and knee osteoarthritis , once-weekly semaglutide 2.4 mg produced: Greater weight loss Significantly larger reductions in knee pain Improved function Obstructive sleep apnea (OSA) The SURMOUNT-OSA phase 3 trials showed that tirzepatide (Zepbound) in adults with obesity and moderate-to-severe OSA: Reduced the apneahypopnea index (AHI) Lowered body weight, hypoxic burden, hsCRP, and systolic BP Improved sleep-related patient-reported outcomes compared with placebo In December 2024, the FDA approved Zepbound as the first medication specifically indicated for moderate-to-severe OSA in adults with obesity , alongside diet and physical activity
and (2) the improvement of autism severity in patient treated for 6 mo with L-carnitine, they also concluded that subsequent studies will be welcome[41]
What Testers Think Could Be Improved While the typical 2:1:1 BCAA ratio itself is solid, the overall dosage is on the lighter side compared to some of the other BCAA supplements available, Pete explained
